Cybersecurity in clinical trials: what the role of AI actually is
Health research has become a genuinely attractive target for cyber attackers, for reasons that aren't specific to any one study: the data is sensitive, often re-identifiable, and increasingly distributed across multiple systems, eConsent, eCRF, ePRO, wearable integrations, each a potential point of entry. Recent work on cybersecurity and compliance in clinical trials looks specifically at where AI fits into this picture, and the honest answer is that it fits on both sides at once.
Where AI genuinely strengthens trial security
The defensive case is fairly concrete. AI-based systems are increasingly used for tasks that are difficult to do reliably at scale by hand:
- Anomaly detection across access logs. A system that flags an unusual access pattern, a login at an atypical time, an unusually large data export, a query pattern that doesn't match normal monitoring behaviour, can catch a compromise far faster than a periodic manual audit.
- Automated compliance checking. Verifying that a system's configuration still matches required security and privacy controls is a task that benefits from continuous, automated checking rather than point-in-time manual review.
- Faster identification of vulnerable integration points. Trials increasingly connect multiple systems together, and each integration is a potential weak point; automated scanning can surface these faster than manual security review of a growing, changing system architecture.
Where AI introduces genuinely new risk
The same technology that strengthens defence also expands the attack surface and introduces failure modes that didn't previously exist in this form:
- AI systems themselves are new targets. A model used for anomaly detection or automated triage can itself be manipulated, through data poisoning or adversarial inputs, in ways a traditional rule-based system can't be.
- Increased data flow between systems for AI training or operation. An AI system that needs data to function is another place that data has to move to, and every additional data flow is another point where something can go wrong.
- A false sense of security from automation. A team that trusts an automated system to catch every anomaly may reduce manual vigilance in ways that leave gaps the automated system wasn't actually built to catch.
What this means for how a trial team should actually think about it
The useful framing isn't "is AI good or bad for trial cybersecurity." It's that AI has become part of the security surface a trial's data protection strategy has to account for, on both the defensive and the risk side, rather than treating it purely as a tool bolted onto an otherwise unchanged security model.
A few practical implications follow:
- Any AI system touching trial data needs its own security review, distinct from the review applied to the underlying eCRF or database it's connected to.
- Automated detection systems should be one layer, not the only layer. Human review and periodic manual audit remain necessary precisely because automated systems have their own failure modes.
- Data flows into and out of AI components need to be mapped explicitly, the same way any other integration point in a trial's data architecture would be, rather than treated as an internal implementation detail.
- Compliance frameworks need updating to actually address AI-specific risks, rather than assuming existing data security policy automatically covers a category of system that didn't exist when the policy was written.
The bigger picture
Trial data security was already a demanding compliance area before AI became part of the conversation, GDPR, 21 CFR Part 11, and GCP data-integrity expectations all predate the current wave of AI tooling. What's changed isn't the underlying standard. It's that the systems a trial's data now passes through have become more numerous and more complex, and each one, AI-based or not, needs to be accounted for individually rather than assumed to inherit security by association with the systems around it.
Treating AI purely as an efficiency tool, without treating it as a genuine part of the trial's attack surface, is the gap most likely to be exploited. Treating it as purely a risk, without recognising what it can genuinely catch that manual review can't, wastes a real defensive capability. The honest position is that it's both, and a trial's security strategy needs to account for both at once.